Literature DB >> 11896517

Risk score for antenatal bacterial vaginosis: BV PIN points.

Lisa M Pastore1, John M Thorp, Rachel A Royce, David A Savitz, Tracy P Jackson.   

Abstract

OBJECTIVE: Develop a clinical risk score to screen for antenatal bacterial vaginosis (BV), irrespective of symptoms. STUDY
DESIGN: Cohort study of 913 pregnant women with last menstrual periods between January 30, 1995 and February 22, 1997. BV was evaluated by Nugent-scored vaginal smears (scores of 7 to 10 considered positive) between 24 and 29 weeks' gestation. Forty-four potential risk factors were assessed.
RESULTS: 17.8% of women had BV, of whom 22% were screened for BV by the usual care provider. Logistic regression-adjusted analyses found six predictors: vaginal pH>4.5 (OR=11.6, 95% confidence interval [CI] [7.8, 17.2]); black race (OR=1.9, 95% CI [1.3, 2.8]); condom use during pregnancy (OR=1.6, 95% CI [1.0, 2.5]); antenatal BV (OR=1.7, 95% CI [1.0, 2.8]); absence of sperm on smear (OR=1.7, 95% CI [1.0, 2.9]); and no history of sexually transmitted diseases (OR=1.6, 95% CI [1.0, 2.5]). Risk score weights were 5 for an elevated vaginal pH and 1 otherwise. The sensitivity and specificity of screening women with scores > or =4 were both 77%; this would involve screening 33% of patients.
CONCLUSION: Approximately 80% of our BV cases were asymptomatic, emphasizing the need for objective risk assessment. Using six factors, clinicians can identify pregnant women at risk for BV.

Entities:  

Mesh:

Year:  2002        PMID: 11896517     DOI: 10.1038/sj.jp.7210654

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  2 in total

1.  Vaginal symptoms and bacterial vaginosis (BV): how useful is self-report? Development of a screening tool for predicting BV status.

Authors:  D B Nelson; S Bellamy; A Odibo; I Nachamkin; R B Ness; L Allen-Taylor
Journal:  Epidemiol Infect       Date:  2007-02-05       Impact factor: 2.451

2.  Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis.

Authors:  Anke Hemmerling; William Harrison; Adrienne Schroeder; Jeanna Park; Abner Korn; Stephen Shiboski; Craig R Cohen
Journal:  Sex Transm Dis       Date:  2009-09       Impact factor: 2.830

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.